Therapy for late post XXXX @entity1165 .

@entity1 @entity64 @entity1165 @entity944 @entity1188 @entity583 @entity943
Non-sustained @entity1165 ( @entity1165 ) in the late post @entity583 ( @entity583 ) period (7-21 days) has been reported to be a predictor of @entity944 . We suspected that @entity1 with 3 beat @entity1165 on Holter monitoring in the late @entity1188 period would demonstrate electrical instability at electrophysiologic studies. Forty-seven @entity1 were identified as having at least 3 beat @entity1165 on Holter monitoring. Eighteen @entity1 refused electrophysiologic studies or were not referred by their attending physician. The mean ejection fraction of this group was 43 +/- 16%. Eight @entity1 have died, 3 sudden deaths in 13 +/- 5 months, a 17% incidence of @entity944 . Twenty-nine @entity1 underwent invasive electrophysiologic studies. Their mean ejection fraction was 37 +/- 7%, and 28 had inducible, 18 sustained @entity1165 and 10 non-sustained @entity1165 . No complications were noted with electrophysiological testing in the post @entity1188 @entity1 . Using programmed electrical stimulation studies an effective antiarrhythmic agent preventing @entity1165 induction (usually experimental) could be found for each @entity1 . After a mean follow-up of 12.5 +/- 4 months, the @entity1 without inducible @entity1165 is alive and 26 of the 28 "inducible" @entity1 are alive and well. Two @entity1 died, one of @entity64 and one due to pump failure following a second @entity583 . No sudden deaths were observed in this group. Two @entity1 had @entity943 and were treated by alternative antiarrhythmic therapy that was also effective at the initial electrophysiologic studies. Thus, PES studies post @entity583 are safe and may be an effective way to assess therapy for @entity1 in the early post @entity583 period, identified at high risk for @entity944 .
